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Abstract
Background: The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory,
platform design. FLAIR was successfully amended to include an emerging promising experimental therapy to expedite
its assessment, greatly reducing the time to reach the primary outcome compared to running a separate trial and
without compromising the validity of the research or the ability to recruit to the trial and report the outcomes. The
methodological and practical issues are presented, describing how they were addressed to ensure the amendment
was a success.
Methods: FLAIR was designed as a two-arm trial requiring 754 patients. In stage 2, two new arms were added: a new
experimental arm and a second control arm to protect the trial in case of a change in practice. In stage 3, the original
experimental arm was closed as its planned recruitment target was reached. In total, 1516 participants will be
randomised to the trial.
Results: The changes to the protocol and randomisation to add and stop arms were made seamlessly without
pausing recruitment. The statistical considerations to ensure the results for the original and new hypotheses are
unbiased were approved following peer review by oversight committees, Cancer Research UK, ethical and
regulatory committees and pharmaceutical partners. These included the use of concurrent comparators in case of
any stage effect, appropriate control of the type I error rate and consideration of analysis methods across trial
stages. The operational aspects of successfully implementing the amendments are described, including gaining
approvals and additional funding, data management requirements and implementation at centres.
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Conclusions: FLAIR is an exemplar of how an emerging experimental therapy can be assessed within an existing trial
structure without compromising the conduct, reporting or validity of the trial. This strategy offered considerable
resource savings and allowed the new experimental therapy to be assessed within a confirmatory trial in the UK years
earlier than would have otherwise been possible. Despite the clear efficiencies, treatment arms are rarely added to
ongoing trials in practice. This paper demonstrates how this strategy is acceptable, feasible and beneficial to patients
and the wider research community.
Trial registration: ISRCTN Registry ISRCTN01844152. Registered on August 08, 2014
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Front-Line therapy in CLL: Assessment of Ibrutinib-
containing Regimes (FLAIR) is a phase III, open-label, ran-
domised, controlled trial (RCT) in patients with previously
untreated chronic lymphocytic leukaemia (CLL) sponsored
and managed by the University of Leeds. The primary aim
of the trial when it was originally designed was to assess
current standard therapy with fludarabine, cyclophospha-
mide and rituximab (FCR) against ibrutinib with rituximab
(IR) in terms of progression-free survival (PFS). At the out-
set of the trial, 754 patients were planned to be randomised
in 4 years, with primary outcomes being available after a
further 4 years of follow-up. The protocol describing the
trial as originally designed has been previously published
[1]. Although the trial was designed to assess a single ex-
perimental arm, it was known that promising therapies
were being assessed in early phase trials, and so the trial de-
sign was kept simple to more easily enable new experimen-
tal treatments to be added if appropriate. The trial opened
to recruitment in September 2014, with 70 UK centres
planned, and has recruited consistently ahead of target.
During recruitment, early evidence emerged of another very
promising treatment combination in this population, ibruti-
nib with venetoclax (I+V). In order to be able to assess I+V
in a phase III trial in the same population in the UK in a
timely manner, it was added into the existing FLAIR trial
framework after 2 years and 10months of the planned re-
cruitment period, when target recruitment was at 84%.
This publication describes the methodological and prac-
tical issues involved in successfully amending the FLAIR
trial to include this promising experimental therapy so that
its assessment could be expedited into a phase III setting.
We detail the pathway for amending this traditional RCT
in order that it became a platform trial with a complex in-
novative design (CID), where the objective of a ‘platform
trial’ is ‘to study multiple targeted therapies in the context
of a single disease in a perpetual manner with therapies
allowed to enter or leave the platform on the basis of a de-
cision algorithm’ [2–5]. A platform trial generally falls
under the umbrella topic of an ‘adaptive design’, which is
described as a ‘clinical study design that uses accumulating
data to decide how to modify aspects of the study as it
continues, without undermining the validity and integrity
of the trial’ [6]. However, we acknowledge that there are
no completely accepted definitions of platform or adaptive
trials. Furthermore, our design does not, strictly speaking,
meet the definition of an adaptive design because the
amendment is not informed by accumulating internal trial
data. The benefits of this aspect are discussed in the ‘Ana-
lysis methods following adaptation of design features with
combination of information across trial stages’ section.
It is described how the strategy used improved the effi-
ciency and relevance of this confirmatory trial, reducing
the time taken to answer new and important clinical
questions without compromising the original design and
maintaining statistical validity. Consequently, this type of
amendment is not only acceptable to, but actively bene-
fits patients, researchers, funders, regulators and the
wider research community.
The original FLAIR trial design
The original design of FLAIR was a phase III, multi-
centre, randomised, controlled, open-label, parallel-
group trial comparing IR against the current standard
FCR, with a total of 754 participants to be randomised
on a 1:1 basis over a 4-year recruitment period. FCR is
given for a maximum of 6 cycles with each cycle being
repeated every 28 days. Participants randomised to re-
ceive IR receive rituximab in the same schedule as for
FCR, and ibrutinib daily for 6 years, until minimal re-
sidual disease (MRD) negativity stopping rules are
reached or until disease progression or withdrawal.
The trial aims were primarily to provide evidence to
assess whether IR is superior to FCR in terms of PFS
and whether IR toxicity rates are favourable as a second-
ary endpoint. Other key secondary endpoints to be
assessed included overall survival (OS), attainment of
undetectable MRD, response to therapy, health-related
quality of life (QoL) and cost-effectiveness, as well as an
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evaluation of discontinuation and re-start of ibrutinib
therapy if indicated based on the levels of residual
disease. Randomisation used minimisation with a ran-
dom element to ensure treatment arms were well-
balanced for the following participant characteristics:
Binet stage (A progressive or B, C), age group (≤ 65
years, > 65 years), gender (male, female) and centre
(all participating centres). Figure 1 illustrates the ori-
ginal participant pathway.
The sample size was based on testing the null hypoth-
esis of no difference in PFS between the treatment arms.
To test a superiority hazard ratio of 0.75 (from 4.5 [7] to
6 years), with an overall two-sided 5% significance level
and 80% power, assuming 4 years recruitment and 4
years follow-up, allowing for 5% drop-out, and inflating
for a planned formal interim analysis on PFS when half
the numbers of events were observed, 754 participants
were required to observe 379 events.
Minimal residual disease negativity treatment break
MRD negativity is defined as the presence of < 0.01%
CLL cells in the peripheral blood or bone marrow. The
detection of MRD above this level after therapy is an in-
dependent predictor of outcome [8], where detectable
disease is prognostic of progression. It is hypothesised
that once a patient’s disease falls below a certain level, it
may reach a point at which the CLL cells cannot grow
back to being detectable or progressing to a level which
requires therapy. In these patients, continuing treatment
may be unnecessary. The FLAIR trial therefore includes
an MRD negativity stopping rule, in which participants
receiving ibrutinib who become MRD-negative stop
therapy after a certain period of time, determined by the
time it took to reach MRD negativity. If participants stop
treatment due to MRD negativity and then relapse at the
MRD level before the end of the trial treatment period,
treatment is restarted to assess whether MRD eradica-
tion is re-achieved and to protect the primary endpoint
of PFS. This is not considered a progression event.
Funding and approvals
FLAIR is partially funded by Cancer Research UK fol-
lowing review and approval by their Clinical Trials Ad-
visory and Award Committee (CTAAC) in November
2012. Janssen Pharmaceuticals provide ibrutinib free of
charge for use in the trial and provide funding via an
educational grant. The trial received ethical approval
from the National Research Ethics Service (NRES)
Fig. 1 Participant pathway into FLAIR prior to the amendment. The experimental arm (IR) is shown in green and the control arm (FCR) in purple
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Committee Yorkshire and The Humber and regulatory
approval from the Medicines and Healthcare Products
Regulatory Authority (MHRA) in June 2014. The trial
was registered on the ISRCTN registry (ISRC
TN01844152) ahead of the first participant being re-
cruited. An independent Data Monitoring and Ethics
Committee (DMEC) and Trial Steering Committee
(TSC) were established during the trial set-up and ap-
proved the original protocol and trial design. The DMEC
and TSC both meet at least annually, and the DMEC re-
view safety reports on a 3-monthly basis.
Accrual
As with all clinical trials, recruitment is monitored
closely by the Trial Management Group (TMG). The
TMG decided that it would only be appropriate to add
arms during recruitment if the trial recruited at least as
well as anticipated and the addition of arms would not
significantly delay the reporting timelines of the original
design. By the end of 2015, it was clear that recruitment
was going to continue at a rate that was 15–20% ahead
of target, and the TMG agreed that this was sufficient
for an amendment to add new arms.
Considerations when designing the original FLAIR trial to
enable amendments
Due to treatment advances, PFS times are increasing,
and whilst clearly beneficial to patients, this presents
challenges for research in ensuring that trials are feasible
and the outcomes remain relevant in the face of a long-
term endpoint. In addition, the drug development envir-
onment in CLL is rapidly changing. At the time of de-
signing the original FLAIR trial, there was a series of
phase II trials planned as part of the Bloodwise Trials
Acceleration Programme (TAP) [9] run through the
University of Birmingham assessing new treatment com-
binations with targeted therapies, some of which
included ibrutinib. The new combinations were hypothe-
sised to give deeper responses than IR, but there was
very little evidence of activity or safety in patients with
CLL. Our options at the time were to either wait for the
phase II outcomes in case they were positive, delaying
the phase III assessment of IR; start the trial as planned,
which would saturate the UK population for the coming
years and deny the investigation of a new promising
combination in a phase III trial; or start the trial but
plan to be able to amend it to include new treatment
arms if appropriate once early phase data were available.
It was clear that in order to speed up the investigation of
promising new therapies and improve the efficiency of
the phase III trials process in CLL to mirror that in
phase II, the last option was necessary. For this reason,
the FLAIR trial had a simple design so it could be more
readily amended.
New treatment arms have rarely been added to on-
going confirmatory trials in practice [10], although phase
III trials are the longest and most expensive part of the
drug development process and doing so would greatly
improve efficiency. The STAMPEDE trial paved the way
in this type of design amendment [11–14], and here we
describe our experiences in an alternative trials setting.
The methodological and practical issues when incorpor-
ating a new experimental research arm into the FLAIR
trial during recruitment are presented, describing how
they were addressed to overcome barriers and ensure
the amendment was a success.
Methods: design of the FLAIR amendment
The emerging combination: ibrutinib + venetoclax
By the end of 2015, early-stage data showed impressive
response rates for venetoclax (V) (ABT-199) when given
in combination with rituximab (V+R) in patients with
relapsed/refractory CLL, and eradication of detectable
MRD in 53% of patients, which had not previously been
seen with any other targeted treatments [15]. Based on
pre-clinical data, it was anticipated that the combination
of V plus ibrutinib (I+V) would be highly synergistic
given the complimentary modes of action of the two
agents, as the ibrutinib arrests CLL cell proliferation and
venetoclax is pro-apoptotic leading to their early cell
death [16, 17]. Since FLAIR incorporates MRD negativity
stopping rules designed to reduce long-term toxicities
and treatment costs, it was important to identify a treat-
ment combination with the greatest chance of inducing
MRD negativity. It was hypothesised that the addition of
venetoclax to ibrutinib would reduce MRD levels faster
and more effectively than those expected with single-
agent I or IR and therefore allow the duration of therapy
based on the level of disease to be reduced, leading to a
reduction in long-term resistance and toxicities and an
overall cost saving. I+V was therefore chosen to be
assessed in the phase II TAP trial ‘CLARITY’ (ISRCTN:
13751862) in 50 patients with relapsed CLL in a non-
randomised setting. Preliminary results from CLARITY
were expected to be available during the first half of
2017, by which time FLAIR would have recruited ap-
proximately two thirds of the planned sample size. The
TMG agreed that these timelines were feasible to allow
I+V to be added to FLAIR as a new arm but only if work
began on designing the amendment and applying for ap-
provals prior to the availability of the phase II safety or
preliminary efficacy results from CLARITY. The ap-
proval applications were made with the caveat that they
would be withdrawn if emerging data indicated. Prelim-
inary safety and early efficacy data from the CLARITY
trial became available in early 2017 and supported the
investigation of I+V in a confirmatory setting [18].
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Inclusion of an ibrutinib monotherapy control arm
In order to protect the trial from changes in practice in
the future, a single-agent ibrutinib arm (I) was also
added alongside I+V as an additional control therapy. At
the time of designing the amendment, FCR was still the
standard of care in front-line CLL and thus was the re-
quired comparator for all experimental therapies. How-
ever, in 2016, the ibrutinib licence was extended to
include use as a single agent for patients with previously
untreated CLL. The TMG therefore felt that an
ibrutinib-containing therapy could become standard of
care in the FLAIR population before the trial was fully
reported. As IR was hypothesised to reach deeper re-
sponses than single-agent ibrutinib, and was being
assessed in clinical trials other than FLAIR, it was un-
clear whether IR or I alone was more likely to become
the standard of care long term in the UK. It was there-
fore proposed to include a single-agent I comparator
arm in addition to IR and FCR at the time of the amend-
ment to add I+V. This mitigated the risk that the out-
comes of the trial would be hugely devalued if it were to
show that I+V was better than FCR, but FCR was no
longer the standard of care.
In order to ensure the timely reporting of trial out-
comes, it was not feasible to include both the IR and I
alone arms as primary comparators to I+V in addition to
FCR. In discussion with Cancer Research UK (CRUK), it
was agreed that a decision would be taken at the end of
the planned recruitment period to the IR vs FCR com-
parison to drop either IR or single-agent I. The decision
on which arm to choose would primarily be made based
on anticipated emerging MRD data from other trials that
were due to report ahead of the decision point.
The amendment therefore included the addition of
two new arms, one experimental and one control. In
addition, there were two new primary hypotheses, one
comparing I+V to FCR and the other comparing I+V to
I or IR.
Stage 2 amended trial design
The amended FLAIR design was a phase III, multi-
centre, multi-arm, randomised, controlled, open, parallel
group trial with participants randomised to receive FCR,
IR, single-agent I or I+V on a 1:1:1:1 basis. The eligibility
criteria remained unchanged from the original design as
did the treatment schedules for FCR and IR. Participants
randomised to I+V receive ibrutinib for 8 weeks before
venetoclax is added over a 5-week dose-escalation phase.
In the single-agent I, IR and I+V arms, ibrutinib and
venetoclax (as relevant) are administered for 6 years,
until the MRD negativity stopping rules are triggered or
until disease progression or withdrawal. If treatment is
stopped and restarted due to MRD levels, participants
randomised to single-agent I or IR receive further
single-agent I, and participants randomised to I+V re-
ceive further I+V. Abbvie provide venetoclax free of
charge for use in the trial and an educational grant for
the additional running costs associated with the new
arms.
The amended trial aims to provide evidence for the fu-
ture first-line treatment of CLL patients by assessing
whether IR is superior to FCR in terms of PFS, whether
I+V is superior to FCR in terms of PFS, whether I+V is
superior to I or IR (as appropriate) in terms of MRD
negativity, and whether IR and I+V toxicity rates are
favourable. The other key endpoints to be assessed re-
main unchanged from the previous design, but now also
compare I+V with FCR and with I or IR. Figure 2 illus-
trates the amended participant pathway.
The sample size for I+V vs FCR was based on testing
the primary null hypothesis of no difference in PFS be-
tween the treatment arms. The assumptions for the clin-
ically relevant effect size differed from those for IR vs
FCR due to the evidence published in 2015 comparing I
with chlorambucil [19], demonstrating that ibrutinib
monotherapy leads to a better PFS than thought in this
population at the time of the original design. To assess a
superiority hazard ratio of 0.69 (for a median PFS in-
crease of 4.5 to 6.5 years) with an overall 5% significance
and 80% power, assuming a 2.5-year recruitment period
and 3.5 years of follow-up, and allowing for a 5% drop-
out rate, 274 participants were required to be concur-
rently randomised to each of FCR and I+V in order to
observe 232 events. A total of 822 participants were
therefore required to be concurrently randomised to
FCR, I or IR, and I+V. A formal interim analysis on PFS
was planned when half of the numbers of events (a total
of 116 progressions and/or deaths) were observed in
FCR and I+V, in order to allow large differences between
the treatment arms to be reported early to the DMEC.
The O’Brien and Fleming alpha-spending function [20]
was used to account for testing at multiple time points
to conserve the overall type I error.
This number of patients provides adequate power to
compare I+V against I or IR in terms of the primary out-
come MRD negativity rate. PFS is included as a key sec-
ondary endpoint, but it is confounded by the MRD
stopping rule potentially affecting the duration of ther-
apy differently in each arm. The analysis of MRD nega-
tivity will be carried out 2 years after the close of the
recruitment. At the time of designing the amendment,
the MRD negativity rates in the ibrutinib-containing
arms were not known, so a range of power calculations
were explored. With 260 evaluable patients in each of
the arms and a 5% two-sided significance level, there is
90% power to detect an improvement from, say 10 to
20%. If there is a larger proportion that becomes MRD
negative with IR, say 20%, there is 90% power to detect
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an improvement to 32.5%, and since a large increase in
MRD negativity would be required in order to justify the
addition of V, the planned number of patients is more
than adequate.
Dropping I or IR in stage 3
The decision on whether the most appropriate compara-
tor for I+V would be I or IR, in addition to FCR, was
discussed with the DMEC and TSC during February
2018, in order to make the amendment in July 2018
once recruitment to the original trial arms had com-
pleted. The emerging evidence from external trials sug-
gested that IR was no better than I in terms of PFS [21]
and also that IR did not lead to good enough rates of
MRD negativity. In addition, MRD negativity results
from IR participants in stage 1 of FLAIR were sum-
marised for the DMEC, and these strengthened the ex-
ternal evidence. The DMEC were able to request this
internal data to aid their decision because it was a non-
comparative summary of a subset of a single arm and
only involved participants who were external to the
concurrent stage 2/3 population for the comparison
under consideration. The DMEC had not reviewed any
comparative efficacy data at the point of discussing the
amended design. It was therefore agreed that the IR arm
would be stopped, and the trial would continue to ran-
domise on a 1:1:1 basis to FCR, I monotherapy and I+V.
There were no changes to the existing treatment sched-
ules or eligibility criteria.
Overview of the trial stages
In total, 1516 participants will be randomised to the
trial. A total of 754 participants are required to be ran-
domised concurrently to FCR and IR (stages 1 and 2)
and 822 participants to FCR, I and I+V (stages 2 and 3).
In addition, 61 FCR patients in stage 2 are included in
both randomisations, and therefore, the total sample size
is less than it would have been in independent trials.
Note that if it had instead been decided that the most
appropriate comparator for I+V was IR, 61 patients
would have been recruited to the single-agent I arm who
would not be included in any primary analysis
Fig. 2 Participant pathway into the FLAIR trial during stage 2. The experimental arms (IR and I+V) are shown in green and the control arms (FCR
and I) in purple.
The primary objectives are:
•To assess IR vs FCR in terms of PFS
•To assess I+V vs FCR in terms of PFS
•To assess I+V vs I or IR, as appropriate, in terms of MRD negativity rate at 24 months post-randomisation
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population; however, this was felt to be an acceptable
risk to the overall strategy. Figure 3 outlines the treat-
ment arms that are included over each stage in the trial.
A dotted line indicates that the participants recruited to
those arms are included in both sets of randomised
comparisons.
The original FLAIR trial was planned to recruit in 4
years. Even with the addition of the extra arms, recruit-
ment completed 2 months ahead of schedule. The
amendment included additional funding to open more
centres, so over 100 were opened rather than the 70 ori-
ginally planned. In this way, the delivery of the original
trial was not compromised by the amendment.
Results
Statistical considerations to ensure unbiased results
Concurrent comparisons
For the analysis of the trial, all primary and secondary
endpoint comparisons will only include patients rando-
mised contemporaneously. That is because if there is a
shift in the patient population due to the design change
or changes in practice over time, it may shift the median
survival and could bias the results [22, 23]. Sixty-one
FCR patients who were included in the original FLAIR
design can also be used as comparators for the I+V arm,
therefore reducing the numbers needed compared to a
new trial. Data from non-concurrent patients across the
whole protocol will be used to carry out exploratory in-
vestigations. There will be more similarities between
these patients than those from separate trials, and having
such a wealth of data on this population could allow
subgroups of patients, for example those with certain
genetic markers, to be investigated to generate hypoth-
eses that could inform future research. This trial was not
designed to report comparisons between the non-
concurrent trial arms single-agent I vs IR, or I+V vs IR,
once it had been decided that IR would be dropped from
stage 3.
Type I error control
There are a number of ways the type I error could be in-
flated or bias introduced in a multi-arm platform trial
design as follows.
Multiple primary hypotheses assessing I+V The I+V
arm is being assessed in two primary hypotheses: against
FCR for PFS and against I for MRD negativity. In order
for I+V to be deemed a ‘success’, it needs to be signifi-
cantly better than both of its control groups. Where
both hypotheses are required to be superior, there is no
inflation of the type I error rate, and therefore, no ad-
justment is required [24].
Multiple hypothesis testing in the same protocol This
protocol allows the opportunity for both IR and I+V to
be declared superior to the current standard within a
primary analysis, therefore increasing the chance of a
type I error for an ibrutinib-containing combination.
Whilst both give the opportunity for a therapy contain-
ing ibrutinib to be declared superior, the aim of giving
the additional treatments in combination with ibrutinib
(rituximab and venetoclax) is to be able to take a break
from ibrutinib therapy and in fact reduce the burden of
ibrutinib compared to the likely future standard of care
of continuous single-agent ibrutinib. Since a type I error
for these comparisons does not directly benefit the same
claim of effectiveness for an experimental therapy,
family-wise type I error rate (FWER) control is not
Fig. 3 Overview of the trial stages
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necessary for this reason [25]. If the two primary hy-
potheses had been assessed in separate protocols no ad-
justment would be required, and in this case, it is
feasible to assume that the questions would have other-
wise been assessed in different trials. Since there is an
overlap in recruitment, some of the control data is
shared between the IR and I+V vs FCR hypotheses.
Howard et al. [25] show that the resulting correlation
between the hypotheses reduces the overall type I error
over what it would have been if they had been assessed
independently, and therefore, FWER adjustment is also
not necessary due to the sharing control data. In sum-
mary, adjusting for multiple testing due to assessing
multiple experimental arms would be an ‘unnecessary
penalty for efficiency’ [26]. This decision was approved
by the DMEC, TSC and CRUK.
Multiple analysis time points In order to account for
the formal interim analyses allowing for early rejection
of the null hypothesis for IR or I+V compared to FCR
based on early evidence of efficacy, the O’Brien and
Fleming alpha-spending function [20] was used. The
method recommends that given a single interim analysis,
the interim results are compared to a p value of 0.005,
and the final results are then compared to a p value of
0.048. This is applied to each of the hypotheses
separately.
Analysis methods following adaptation of design
features with combination of information across trial
stages It can be seen from Fig. 3 that the trial consists
of three stages, each with different randomisation op-
tions. The decision to add the new arms was made with-
out reference to internal trial data. At the end of stage 2,
after the IR vs FCR randomisation had reached its target
recruitment, IR was dropped from the trial. The decision
to drop IR rather than I was made primarily based on
the data external to the trial, but also on a summary of
MRD results from participants randomised to IR in stage
1 only. This has no implications for the analysis of the
IR vs FCR comparison across stages 1 and 2 because the
planned recruitment had completed at the time that the
amendment to drop IR was made. It also has no implica-
tions for the analysis of the I+V vs I comparison across
stages 2 and 3 because the data summarised was for the
IR arm from stage 1 participants only, and these are ex-
ternal to the concurrent randomisation across stages 2
and 3. In addition, summarising a subset of MRD results
for IR patients for the DMEC does not affect the type I
error for the final analysis of PFS for IR vs FCR because
no randomised comparison was carried out.
Since the decision to add (and stop) arms was not in-
formed by any analysis of data internal to the existing
hypotheses at the time of the amendment, the trial is
not truly adaptive because the second stage is not in-
formed by the first stage data for each hypothesis.
Therefore, adaptive analysis methods are not required,
and each hypothesis is analysed by pooling the data over
the relevant stages. A multivariable Cox regression is
planned to analyse the PFS primary endpoints, and a
multivariable logistic regression is planned for the binary
primary endpoint of achievement of MRD negativity.
Whilst the key eligibility criteria did not vary across the
stages, it is possible that the different treatment options
attract slightly different patients. In the first stage, there
was a 50% chance of receiving ibrutinib (IR); in the sec-
ond stage, this increased to a 75% chance (IR, I or I+V);
and in the third stage, 67% (I or I+V). In addition, the
number of centres increased leading up to the second
stage. In case of any stage effects caused by the changing
treatment options or centres, the planned multivariable
regressions for all analyses of primacy include ‘trial stage’
as a covariate as well as the stratification factors: disease
stage, age group and gender [27].
Other statistical details
In addition to the key points detailed above, the follow-
ing were also considered to ensure the ability of the trial
to answer all the primary hypotheses.
Power The new hypotheses comparing I+V concur-
rently against FCR and I were both adequately powered.
The design for the original hypothesis was unchanged by
the addition of the new arms, so the power calculation
remained appropriate. In addition, since there was no
adjustment to the significance level for multiple hypoth-
esis testing, the power remained adequate.
Randomisation and allocation Randomisation was by
minimisation with stratification and a random element
[28], and the stratification factors were unaltered for the
duration of the trial. At each stage, the minimisation al-
gorithm was reset. This was felt appropriate so that each
set of concurrent data within each stage remains bal-
anced, and there were enough patients in each stage that
the arms were generally well balanced overall. Continu-
ing the minimisation algorithm would not be appropri-
ate when adding an arm as all totals would be zero for
the new arm at first, distorting the algorithm. There is
no reason why resetting the minimisation algorithm
would introduce any bias.
It was decided to maintain an even allocation ratio to
all arms in all stages, regardless of the number of experi-
mental treatments. There are views in the literature [10,
29] that randomising a higher proportion to control can
be more efficient in terms of total patient numbers
needed when there is more than one experimental arm,
although this is less clear when there are multiple
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control arms, or that all arms should complete recruit-
ment at the same time to avoid a third stage. However,
having a different allocation ratio in different stages for a
single hypothesis would complicate the power calcula-
tion and affect the analysis [22].
Implementation and operational requirements
Timelines
The timeline of key events from opening the FLAIR trial
and deciding to progress the amendment to opening the
new arms are summarised in Table 1. Almost as soon as
stage 1 opened to recruitment, discussions began about a
possible amendment. The decision to progress the amend-
ment to include an I+V experimental arm was taken after
the trial had been open for 1 year. It took a further 2 years
before stage 2 opened. These timelines were driven by the
lack of availability of the early-phase data until mid-2017,
but it would have been difficult to reduce this set-up time
much for reasons described below.
Approvals and funding
Oversight committees The concept of adding new arms
to FLAIR was initially discussed with the DMEC and
TSC in October 2015. Neither committee had seen any
internal efficacy data; the DMEC had only reviewed
safety data, and the formal interim efficacy analysis was
not triggered until after the implementation of both
amendments. Both groups gave their approval for the
necessary funding applications to proceed and agreed
that they would approve the new design once funding
was in place. The TSC includes a patient and public in-
volvement (PPI) representative who was actively in-
volved in the discussions and the decision to approve
the amendment and felt that the efficiency of the design
would be beneficial to patients. The final amended trial
design was reviewed and approved by the oversight com-
mittees in February 2017.
The amendment was also presented to and approved by
the NCRI CLL Subgroup Committee and the NCRI
Haemato-oncology Clinical Studies Group (CSG). Both
groups were very supportive of the amended design, which
was important as they represent the FLAIR principal investi-
gators from participating centres and patient groups.
Cancer Research UK A no-cost amendment application
was submitted to the CRUK Clinical Research Commit-
tee in November 2015 for review by the committee in
May 2016. This process included an international peer
review by four reviewers. One of the peer reviewers
identified I+V as a combination with ‘game-changing
potential’ and another that ‘with the amended design of
adding ibrutinib and ibrutinib + venetoclax arms, this
trial has the potential to help define the standard for
frontline CLL treatment worldwide’. Some of the re-
viewers supported the design methodology of adding
new arms with one saying ‘As the availability for novel
agents increases across all types of cancer, studies such
as this can be looked at as a model for efficiently an-
swering key questions in a field.’ and another that ‘The
planned amendment is essential for this trial to ensure
that the conclusions remain relevant when it is due to
report’. However, others were concerned about the com-
plexity of the amended trial design and if this would im-
pact deliverability, whether it was reasonable not to
adjust for multiple testing given the shared control pa-
tients, whether the design would be supported by the
relevant pharmaceutical companies and whether changes
in practice could affect the trial long term. All of these
points were addressed to the satisfaction of the commit-
tee, and approval was granted.
Pharmaceutical companies Due to the relatively short
timelines between I+V emerging as an important treat-
ment combination and the original FLAIR design meet-
ing the recruitment target, discussions with
pharmaceutical companies had to happen in parallel
with the amendment application to CRUK. The
amended design included the use of the new Investiga-
tional Medicinal Product (IMP), venetoclax, manufac-
tured by Abbvie and a considerably higher number of
patients receiving ibrutinib. In advance of the design be-
ing discussed with the DMEC, TSC and NCRI commit-
tees, initial discussions had been held with Abbvie to
Table 1 Timeline of events from trial opening to adding the
new arms
Date Task
Q3 2014 Stage 1 open to recruitment September 2014: FCR vs IR
Q3 2015 Emerging response data for venetoclax
FLAIR recruiting ahead of target
Decision to progress amendment




Q1 2016 AbbVie agreed to support amendment subject to contract
Q2 2016 CRUK approval
Janssen agreed to support amendment subject to contract
Protocol amendments began
Q1 2017 Amendments to protocol and PIS finalised
DMEC/TSC final approval
MHRA substantial amendments submitted
Q2 2017 Ethics substantial amendments submitted
Preliminary safety data for I+V became available
CRFs and database amendments finalised
Contracts signed and all approvals had been received
Q3 2017 Stage 2 open to recruitment: FCR vs IR vs I vs I+V
Amendment randomisation became live July 2017
Original randomisation system switched off August 2017
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establish provisional support for the design. A formal
funding application was submitted to them in November
2015, and in February 2016, Abbvie agreed to provide
free venetoclax and an educational grant for the add-
itional running costs associated with the new arms, sub-
ject to successful contract negotiation. In June 2016,
Janssen, the manufacturer of ibrutinib, agreed to provide
free ibrutinib for the additional participants in the new
arms and associated IMP distribution costs.
To finalise this additional support, a contract amend-
ment was required with Janssen and a new contract was
required for Abbvie. These contracts were both signed
in May 2017. Contract negotiation is a common factor
impacting trial set-up times and delaying trials opening
to recruitment. These negotiations are made more com-
plex by having multiple pharmaceutical funders and ne-
gotiating contracts that comply with charitable funders’
terms and conditions. It was arguably simpler adding an
additional pharmaceutical partner after the trial had
opened as the principles around data sharing and intel-
lectual property had already been agreed with one com-
pany, so there was an understanding that those terms
would be equivalent for new funders.
Ethical and regulatory Protocol development, including
associated documentation such as the participant informa-
tion sheet (PIS), was finalised in February 2017 following a
number of reviews both by the TMG and by pharmaceut-
ical companies. The PIS was also reviewed by the PPI rep-
resentatives on the NCRI CLL Subgroup Committee.
Substantial amendments were submitted to the MHRA
and ethics committee in March and April 2017, respect-
ively. Ethics approval was received promptly within
2 weeks of the submission, but MHRA approval was not
received until May 2017. This was delayed as the MHRA
requested additional information about the safety of the
I+V combination.
Data management considerations
The trial case record forms (CRFs) were updated in
line with the trial protocol and were finalised in April
2017. It was decided to amend the existing trial data-
base rather than having a separate database for the
new comparisons. This added some limitations in
terms of how data for the new arms were collected as
it needed to work within the existing database struc-
ture, but did not compromise the quality of the data
that was collected for the analyses in terms of data
compliance or the number of data queries raised. A
new randomisation system was implemented for the
four-arm design which meant all centres had to be
re-activated on the system.
Implementation at centres
A key consideration when the amendment was designed
was that the addition of new arms should not signifi-
cantly delay the reporting of the FCR vs IR comparison
beyond the original planned timelines. As the trial was
recruiting ahead of target, and the number of recruiting
centres was planned to be increased from 70 to 110, the
impact on the original analysis timelines was minimal.
Set-up of the additional centres started ahead of the
amendment opening to further increase the recruitment
rate. Five existing centres decided not to participate in
the amended trial, four due to the lack of capacity and
one because they were unable to cover the cost of MRD
testing which was allocated as a treatment cost.
The new randomisation system went live at the begin-
ning of July 2017. Thirty-nine centres opened to the new
design within the first week. It was agreed that the old
randomisation system would be switched off at the end
of August 2017 with all centres needing to have ap-
provals for the amendment in place before then or they
would have been suspended to recruitment. Sixty-eight
centres opened before the original randomisation system
was closed, rising to over 100 centres in the following
months.
Discussion
The strategy of incorporating a new experimental treat-
ment into the FLAIR framework was successful and
hugely advantageous, without compromising either the
original or new research goals. In this way, we were able
to incorporate emerging evidence to test two experimen-
tal therapies instead of one, keeping the trial outputs
timely and relevant and minimising resources. There are
many advantages to this strategy, and although there
were also challenges, these were not insurmountable.
Challenges
Perceived risk
Adapting a trial in any way introduces complexities,
both real and perceived. A comment from a CRUK peer
reviewer was ‘Trial design is now more complex, so add-
itional risk that not all components will be completed as
planned’. This general feeling that the more complex the
design, the more risk is involved both operationally and
statistically was echoed in the discussions with clinical
and patient representative members of the NCRI CLL
Subgroup. Whilst a larger and longer trial with more
components will naturally carry more risk, the trials
team were careful to consider any potential sources of
bias or disadvantages and address them, as discussed
throughout this manuscript. The original trial question
of IR vs FCR is largely unaffected by the addition of the
new arms. The number of planned centres were in-
creased from 70 to 110 to ensure that recruitment to the
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original arms was not negatively impacted by the
addition of the new arms, and in fact, this comparison
recruited ahead of target even with the amendment. The
analysis is planned when the data in these arms are ma-
ture and without reference to the new arms, so the trial
outcomes are not delayed by the amendment. The ana-
lysis includes trial stage as a covariate to account for any
potential changes to the population caused by adding
the arms and centres. Each primary hypothesis is fully
powered and is assessed based on concurrently recruited
patients only, which protects against changes in the trial
population over time, and statistical aspects relating to
error rates due to sharing a protocol and control data
have also been considered in detail as described
previously.
Timelines of implementation
In order for the confirmatory assessment of the emerging
therapy to be as seamless as possible following the phase
II Bloodwise TAP CLARITY Trial, the amendment was
planned and funding applications submitted approxi-
mately 18months prior to the availability of the CLARITY
trial safety and activity data. At the time of starting the
process, there was evidence of activity and safety of I+V in
mantle cell lymphoma, but the combination had not yet
been assessed in CLL. Due to the length of time it takes to
obtain funding and approvals, the amendment was set in
motion with the caveat that the applications would be
withdrawn and the amendment dropped if the phase II
data was not acceptable. Any changes to treatment sched-
ule or safety monitoring that were required for CLARITY
would have also been implemented into the FLAIR
amendment. Had the emerging results been unacceptable
and the amendment dropped, there would have been an
amount of work done that had taken place unnecessarily,
but this is similar to the risks associated with any new trial
grant application. Work on protocol development and
other amendment processes was started before contracts
with the pharmaceutical funders were signed which also
presented a financial risk; however, this was felt to be ac-
ceptable based on the preliminary approvals from both
companies.
The decision to progress the FLAIR amendment was
made 2 years before the amendment opened. This length
of time was necessary for an amendment this substantial,
although this may not be anticipated by collaborators.
Many of the trial management processes are similar to
those in setting up a new trial and take almost as long to
implement, especially where funding needs to be sought.
Operational challenges
Planning and setting-up such a substantial amendment
at the same time as running the large, fast-recruiting
phase III trial presents challenges. In terms of resource
management, it is equivalent to running a large trial at
the same time as setting up a separate trial which signifi-
cantly impacts the workload for a single dedicated trials
team. It was necessary to increase staffing and to have
some staff moved off other projects to focus solely on
FLAIR. As an indicator of resource required, the overall
staff full-time equivalent (FTE) for the amendment was
equivalent to the FTE in the original design, therefore
doubling the number of staff needed to successfully de-
liver the trial. The drivers for this were the increase in
sample size from 754 to 1516, the extended trial dur-
ation, increase in the number of participating sites and
complexities of the new design such as additional IMP
management. Defining the requirements of the original
trial alongside the amendment and balancing between
those priorities required active management and flexibil-
ity by the trial team. It was essential for the team to re-
main mindful of the existing trial timelines, and not
inadvertently delay milestones due to the additional
workload.
There was a new feasibility consultation performed
with existing trial sites early on in the amendment
process, rather than assuming enthusiasm. Larger cen-
tres and those recruiting well were generally very posi-
tive and reported finding it easier to implement than
opening a new trial as they already had momentum and
familiarity with the systems. In addition, having a higher
chance of participants being allocated an experimental
treatment was appealing. However, as the new drug was
a higher risk, it meant a few smaller sites were not able
to participate and subsequently withdrew from the trial.
The FLAIR team thank all participating sites for their
dedication and the time and effort they put into making
this amendment a success.
Planning for future potential changes in practice
One of the concerns with long trials, particularly those
with different hypotheses being assessed at different
times such as in platform designs, is that practice will
change and the outcomes become less relevant or the
standard control therapy will be superseded. In order to
pre-empt and protect against this, a single-agent ibruti-
nib control arm was added concurrently to the I+V arm,
so two different control groups were included. It is
somewhat unusual for a confirmatory trial to include
two control groups, and clearly, the number of patients
needed is increased compared to a standard randomised
controlled trial. However, there was reasonable evidence
that the standard therapy could change over the life of
the trial, so this measure was felt to be necessary. The
strategy of having two controls allowed I+V to be
assessed against the most relevant therapies without
delaying the research. During the course of the trial, if
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FCR was superseded, it could be dropped from the ran-
domisation without compromising the trial outcomes.
A key point raised within reviewers’ comments was
that the trial is not designed to report confirmatory
comparisons between the non-concurrent arms: I mono-
therapy and IR; or IR and I+V. Trials comparing I and
IR were ongoing [21, 30], and whilst early evidence sug-
gested that IR is not better than I, if further evidence
emerges that shows otherwise, it is possible to directly
compare endpoint data between the 122 contemporan-
eous patients for each comparison as an exploratory in-
vestigation to inform future trial designs. In addition, we
would have data on MRD negativity, treatment duration
and safety rates as well as health economic evaluations
for single-agent I, IR and I+V from within the FLAIR
trial to input into this assessment. The outcomes from
non-contemporaneous trial arms will be treated as they
would be had they arisen from different trials.
Conclusions
We have described how the FLAIR trial was able to suc-
cessfully provide a platform for an emerging new therapy
to be assessed within an existing confirmatory trial
framework. It is demonstrated that despite some chal-
lenges, this type of adaptation is feasible, acceptable and
can give statistically unbiased outcomes. In addition, any
logistical challenges were not insurmountable. This
strategy offered substantial gains in efficiency for asses-
sing the emerging therapy. For the original trial, it took
over 2.5 years from submission of the outline funding
application to the first centre opening, and 3.5 years for
all centres to be open, which is not unusual for a con-
firmatory trial. By amending FLAIR rather than planning
a new trial, the new hypotheses were incorporated al-
most seamlessly following on from the external phase II
assessment, completely eliminating the time period be-
tween confirmatory trials. Due to opening additional
centres even before the amendment was implemented,
the original hypothesis is not delayed in recruitment or
reporting. The primary assessment for the new hypoth-
esis is planned just 1 year later than for the original,
which is a saving of many years over planning and run-
ning a new trial. In addition, these hypotheses are able
to be assessed in the same population at the same time
without competing with one another.
The key benefit of this type of amendment relates to
efficiency rather than necessarily being financial. Whilst
there are some wider cost savings linked to reduced
centre set-up times, some oversight functions and site
monitoring, for example, the savings are hard to quantify
and certainly would not be a driver in the decision to
amend a trial in this way. Understanding the efficiencies
of platform trial design warrants further investigation,
and integration of data from other platform trials would
be beneficial in this area.
The ability to amend FLAIR by adding new treatment
arms has greatly benefitted patients because they have
access to the latest therapies sooner. This was discussed
in an article in the BBC News [31] which describes the
extremely promising results from the I+V investigation
in the phase II CLARITY trial, and how the use of a flex-
ible trial design enabled this treatment to be quickly in-
corporated into a randomised confirmatory trial. The
Trial Management Group continues to explore oppor-
tunities to further adapt the trial in response to emer-
ging evidence in the field. A treatment arm for patients
with genetically high-risk CLL is under development and
would broaden the eligibility criteria of the trial to allow
access for a patient group which are excluded from
many clinical trials.
The FLAIR amendment has demonstrated that adapt-
ing a trial by adding experimental arms is feasible in
practice without compromising the statistical validity or
logistical integrity of the trial.
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